Recombinant Mouse CCL19/MIP-3 beta protein (rFc Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
rFc Tag
Activity
not tested
Cat no : Eg3124
Validation Data Gallery
Product Information
Purity | >90 %, SDS-PAGE |
Endotoxin | <0.1 EU/μg protein, LAL method |
Activity |
Not tested |
Expression | HEK293-derived Mouse CCL19 protein Gly26-Ser108 (Accession# O70460) with a rabbit IgG Fc tag at the C-terminus. |
GeneID | 24047 |
Accession | O70460 |
PredictedSize | 35.2 kDa |
SDS-PAGE | 38-48 kDa, reducing (R) conditions |
Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Inflammation is considered a vital component of the tumor microenvironment, and it is proposed as a hallmark of cancer. Chemokines are a group of chemotactic cytokines that orchestrate the proper movement of immune cells through specific binding to corresponding receptors, thus contributing to the process of immune regulation and inflammatory response. Among CC chemokines, CCL19 is almost the most well-known chemokine for its homeostatic and physiological functions in the development of primary and secondary lymphoid organs. CCL19 is highly expressed in lymphoid organs, including the thymus and lymph nodes. Therefore, it exerts physiological and homeostatic functions in developing the immune system. In addition, CCL19 has been confirmed to be moderately expressed in non-lymphoid organs, including the colon and trachea. Moreover, the small intestine, lung, spleen, kidney, and stomach express CCL19 at low levels.
References:
1.Colotta F. et al. (2009) Carcinogenesis 30, 1073-81. 2.Bhat AA. et al. (2021) Mol Cancer. 20, 2. 3.Link A. et al. (2007) Nat Immunol. 8, 1255-65. 4.Baggiolini M. et al. (2001) J Intern Med .250, 91-104. 5.Kawashima D. et al. (2005) J Clin Pathol .58, 1057-63.